Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)
Q4 2023 Kodiak Sciences Inc Earnings Call
Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.